SEC Chair: Publicly traded company executives should 'practice good corporate hygiene'

Biotech company Moderna, which is testing one of the leading coronavirus vaccine candidates, priced an offering of 17.6 million new shares at $76 each, the company said late Monday. The announcement comes after Moderna reported positive data on its early-stage human trial for a Covid-19 vaccine earlier Monday. The closely watched vaccine trial produced Covid-19 antibodies in all 45 participants, sending the company’s stock surging nearly 20% to close at $80 a share. SEC Chairman Jay Clayton joins "Squawk Box" to discuss.